Gabapentin Capsule
Product Images NDC 72162-2139

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 72162-2139). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

An illustration showing a formula for calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, with an adjustment factor for female patients.*

FDA Label Image

Figure1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure diagram of Gabapentin showing its molecular arrangement including a cyclohexane ring and attached functional groups.*

FDA Label Image

Image 1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph showing mean pain score over 8 weeks comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks, including a 4-week dose titration and a 4-week fixed dose period. The y-axis represents mean pain score from 0 to 10. Gabapentin shows a steady decrease in pain score over time, while placebo remains relatively constant.*

FDA Label Image

Image 2 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

A line graph comparing mean pain scores over seven weeks during treatment with placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. It shows a 3-week dose titration period followed by a 4-week fixed dose period, illustrating lower pain scores for both Gabapentin doses compared to placebo.*

FDA Label Image

Image 3 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing the response rates between placebo (PBO) and Gabapentin (GBP) at different dosages across two studies. Study 1 shows 12% response for placebo and 29% for GBP 3600 mg; Study 2 shows 14% for placebo and 32% and 34% for GBP 1800 mg and GBP 2400 mg respectively. Statistical significance is noted with p-values less than 0.01 and 0.001.*

FDA Label Image

Image 4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot chart showing difference (%) on the y-axis versus daily dose (mg) on the x-axis for Gabapentin. It compares three studies labeled as STUDY a, STUDY b, and STUDY c, with data points at various doses ranging from 600 mg to 1800 mg.*

FDA Label Image

Label (Lbl721622139)

Label for Gabapentin Capsules USP 300 mg by Bryant Ranch Prepack, available in a bottle of 100 capsules. The label includes storage instructions (20° to 25°C, excursions permitted between 15° to 30°C), dispensing guidance, and a barcode. Manufactured by ACI Healthcare Limited.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.